A 28-year-old woman with mild persistent asthma presents for management. She has symptoms 3–4 days per week and nocturnal symptoms 1–2 times per month. She has never used an inhaled corticosteroid. Which inhaled corticosteroid is the drug of choice for initiation of controller therapy in this patient?

Explanation

## First-Line Inhaled Corticosteroid in Mild Persistent Asthma **Key Point:** Beclomethasone dipropionate (BDP) is the most widely recommended and cost-effective first-line inhaled corticosteroid for mild persistent asthma, particularly in Indian and resource-limited settings, as endorsed by GINA 2023 and Indian asthma guidelines. ### Rationale for BDP as First-Line **High-Yield:** BDP is the preferred starting ICS because it offers: - Proven efficacy at low doses (200–400 μg/day HFA-BDP equivalent) - Decades of safety data with well-characterized systemic absorption profile - Extensive first-pass hepatic metabolism limiting systemic bioavailability - Cost-effectiveness and wide availability in multiple devices - Guideline endorsement as a preferred low-dose ICS option in Step 2 therapy (GINA 2023) ### Comparison of Inhaled Corticosteroids | Drug | Relative Potency | Low Dose (μg/day) | Systemic Bioavailability | First-Line Status | |------|-----------------|-------------------|--------------------------|-------------------| | **Beclomethasone (HFA)** | Medium | 200–500 | Very low (~1%) | **Yes — preferred in Indian/resource-limited settings** | | Fluticasone propionate | High | 100–250 | Low (~1%) | Yes — co-equal first-line per GINA | | Mometasone furoate | Medium–High | 110–220 | Very low | Alternative, not universally first-line | | Ciclesonide | Medium (prodrug) | 80–160 | Very low | Alternative, not universally first-line | **Clinical Pearl:** GINA 2023 lists both BDP and fluticasone propionate as acceptable low-dose ICS options for Step 2 (mild persistent asthma). However, in the Indian context (KD Tripathi, Indian asthma guidelines), BDP is specifically highlighted as the **drug of choice** for initiating ICS therapy due to its long track record, affordability, and availability. Fluticasone propionate is equally efficacious but is not preferentially ranked above BDP for mild disease initiation in Indian pharmacology curricula. **Important Correction from Prior Explanation:** Fluticasone propionate is NOT reserved exclusively for moderate-to-severe asthma. It is a co-equal first-line agent per GINA. However, in the context of Indian pharmacology examinations and KD Tripathi, BDP retains its status as the prototypical first-line ICS. ### Why BDP Over Others in This Clinical Context 1. **Guideline Endorsement (Indian):** KD Tripathi 8e and Indian asthma guidelines recommend BDP as the first-choice ICS for initiating controller therapy. 2. **Safety Profile:** Minimal systemic effects; ideal for long-term use in mild disease. 3. **Cost-Effectiveness:** Most affordable option, critical in resource-limited settings. 4. **Efficacy:** Achieves adequate control at low doses without resorting to higher-potency agents unnecessarily. [cite: KD Tripathi Essentials of Medical Pharmacology 8e, Ch 28; GINA 2023 Report, Step 2 preferred controller therapy]